(Q38167264)

30 August 2017

Non-alcoholic fatty liver disease: a diabetologist's perspective (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

30 August 2017

1 reference

non-alcoholic fatty liver

inferred from title

1 reference

1 reference

Joseph M Pappachan

1

1 reference

30 August 2017

Farrah A Antonio

series ordinal

2

1 reference

30 August 2017

Mahamood Edavalath

series ordinal

3

1 reference

30 August 2017

Arjun Mukherjee

series ordinal

4

1 reference

30 August 2017

28 November 2013

1 reference

30 August 2017

1 reference

30 August 2017

45

1 reference

30 August 2017

3

1 reference

30 August 2017

344-353

1 reference

https://scigraph.springernature.com/pub.10.1007/s12020-013-0087-8

30 August 2017

0 references

cites work

GI epidemiology: nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Skeletal muscle insulin resistance promotes increased hepatic de novo lipogenesis, hyperlipidemia, and hepatic steatosis in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Clinical Review: Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Steatohepatitis: a tale of two "hits"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Obesity and inflammation: epidemiology, risk factors, and markers of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Liver and diabetes. A vicious circle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Nonalcoholic steatohepatitis: definition and pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

A pathogenetic link between non-alcoholic fatty liver disease and celiac disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Relationship between insulin resistance, inflammation and liver cell apoptosis in patients with severe obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Silent non-alcoholic fatty liver disease-a clinical-histological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Noninvasive assessment of hepatic steatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

The utility of radiological imaging in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Diagnosis and evaluation of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Increased risk of type 2 diabetes in subjects with both elevated liver enzymes and ultrasonographically diagnosed nonalcoholic fatty liver disease: a 4-year longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Long-term follow-up of patients with NAFLD and elevated liver enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Assessment of endothelial function in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Posttransplant metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

The natural history of nonalcoholic fatty liver disease: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Resistance training improves metabolic health in type 2 diabetes: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Administration of ghrelin improves inflammation, oxidative stress, and apoptosis during and after non-alcoholic fatty liver disease development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Current treatment of non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Health benefits of gastric bypass surgery after 6 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0087-8

Increasing whole grain intake as part of prevention and treatment of nonalcoholic Fatty liver disease.

21 January 2018

1 reference

12 December 2020

A position statement on NAFLD/NASH based on the EASL 2009 special conference

1 reference

12 December 2020

Dipeptidyl peptidase IV inhibitors: therapeutic potential in nonalcoholic fatty liver disease

1 reference

12 December 2020

The effects of diet-induced obesity on hepatocyte insulin signaling pathways and induction of non-alcoholic liver damage

1 reference

12 December 2020

Transient elastography in non-alcoholic fatty liver disease

1 reference

12 December 2020

Non-alcoholic steatohepatitis: another disease of affluence

1 reference

12 December 2020

Fatty liver: a study of 270 patients with biopsy proven fatty liver and review of the literature

1 reference

12 December 2020

Gastrointestinal complications of diabetes mellitus

1 reference

12 December 2020

Prevalence and clinical associations of posttransplant fatty liver disease

1 reference

12 December 2020

Independent Association between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: A Systematic Review and Meta-Analysis

1 reference

12 December 2020

Ghrelin: a new treatment for non-alcoholic fatty liver disease?

1 reference

12 December 2020

Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis

1 reference

12 December 2020

Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease

1 reference

12 December 2020

Sonographic diagnosis of fatty liver using a histogram technique that compares liver and renal cortical echo amplitudes

1 reference

12 December 2020

How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences?

1 reference

12 December 2020

Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease

1 reference

12 December 2020

Anti-oxidant therapy in non-alcoholic fatty liver disease: the role of silymarin

1 reference

12 December 2020

Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease

1 reference

12 December 2020

Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis

1 reference

12 December 2020

Increasing prevalence of lifestyle diseases: high time for action

1 reference

12 December 2020

Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD).

1 reference

12 December 2020

Liver fat content is associated with an increase in cholesterol synthesis independent of statin therapy use in patients with type 2 diabetes

1 reference

12 December 2020

Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound

1 reference

12 December 2020

Non alcoholic fatty liver disease and metabolic syndrome.

1 reference

12 December 2020

10.1007/S12020-013-0087-8

Identifiers

DOI

1 reference

release_rkpgb7l7unhovldktqi4xygvsy

30 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/rkpgb7l7unhovldktqi4xygvsy

24 November 2022

mapped directly with Wikidata item

1 reference